問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Endocrinology

Division of Cardiovascular Diseases

Division of General Internal Medicine

Far Eastern Memorial Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2025-12-16

王景淵 (王治元)WANG, CHIH-YUAN
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

  • ejchung@gmail.com

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王景淵 (王治元)

List

29Cases

2026-02-01 - 2029-02-24

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2025-09-30 - 2032-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2026-02-02 - 2031-04-05

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2008-10-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-01-01 - 2010-06-30

Phase III

Evaluation Dapagliflozin inhibitor and with Metformin and controls DPP-4 (Sitagliptin) and received unilateral Metformin Metformin therapy with poor glycemic control in diabetic adult still disease international efficacy and safety of 24 weeks after a second type, multi-center, Random assignment, parallel, double-blind, curative effect control group, phase III clinical trial.

  • Condition/Disease

    Patients with type 2 diabetes who still have poor blood sugar control after taking at least 1,500 mg of Metformin daily

  • Test Drug

    Dapagliflozin/placebo; Sitagliptin/placebo

Participate Sites
8Sites

Terminated8Sites

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助
China Medical University Hospital-Taipei

未分科

陳涵栩
Taipei Veterans General Hospital

Division of Endocrinology

2014-12-30 - 2019-12-31

Phase III

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

  • Condition/Disease

    major adverse cardiovascular event, MACE

  • Test Drug

    Epanova®

Participate Sites
7Sites

Terminated6Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2012-02-01 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-03-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-02-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB